Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/ba/a0/45/baa04564-7b09-986d-2615-af6588f04f0e/mza_2818871061462724502.jpg/600x600bb.jpg

Medical Digest & Congress Report

Medical Congress News

575 episodes

21 hours ago

The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.

Health & Fitness

RSS

All content for Medical Digest & Congress Report is the property of Medical Congress News and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/16079020/16079020-1630667307527-f22dc9ee28cb5.jpg

Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial - report from ESMO 2025

Medical Digest & Congress Report

6 minutes 13 seconds

2 weeks ago

Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial - report from ESMO 2025

Professor Danny Rischin shares his thoughts on the analysis of second primary cutaneous squamous cell carcinoma tumors reported during the C-POST trial were presented at the ESMO Congress 2025. The study is a randomized phase III study of adjuvant cemiplimab vs placebo for high-risk CSCC.

Video: https://medicaldigest.org/scientific-contents/interview:analysis-second-primary-cutaneous-squamous-cell-carcinoma-tumors-reported-during-c-post-trial